These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28751288)

  • 1. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
    Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer.
    Gonssaud B; Goussot V; Berriolo-Riedinger A; Saïtta-Aribau E; Coutant C; Cochet A; Fumoleau P; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):421-429. PubMed ID: 28751287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CA 125 assay in the extension assessment of newly diagnosed breast cancers: why and how?].
    Laffont A; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2018 Oct; 76(5):553-561. PubMed ID: 30154065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
    Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
    Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.
    Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Altorjai G; Locker GJ; Mader R; Zielinski CC; Steger GG
    BMC Cancer; 2006 Mar; 6():81. PubMed ID: 16563172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer].
    Konan S; Goussot V; Desmoulins I; Lorgis V; Coutant C; Fumoleau P; Beltjens F; Dalban C; Lizard S; Riedinger JM
    Bull Cancer; 2015 Oct; 102(10):834-44. PubMed ID: 26422277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
    Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
    Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
    Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
    Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.